# DARPA Awards RxMP $10.7M RMP-402 Contract

On October 20, 2026, the Defense Advanced Research Projects Agency (DARPA) awarded RxMP Therapeutics, Inc. up to $10.7 million through its RAPIID program to advance RMP-402, a hemostatic therapy intended for military and civilian use. The contract funds remaining investigational new drug (IND)-enabling work, manufacturing scale-up, and preparation of the IND application. This is an announced award, not an open solicitation, and no contract number or procurement contact was provided.

- The award identifies DARPA demand for development and manufacturing capabilities supporting hemostatic therapies with potential defense and civilian applications.
- Companies with relevant biomedical development or scale-up capabilities can use the award as a market signal, but should not treat it as an active bid opportunity.
- RxMP’s work is aimed at preparing an IND application; the signal does not specify an FDA decision, product approval, or a future procurement timeline.

**Jurisdictions:** federal
**Industries:** Defense & Military, Healthcare
**Topics:** Grants & Funding
**Published:** October 20, 2026

### Government Entities
- Defense Advanced Research Projects Agency (DARPA)
- U.S. Department of War (DoW)
- U.S. Food and Drug Administration (FDA)

### Vendors
- RxMP Therapeutics, Inc. (awardee)

### Sources
- [DARPA Awards up to $10.7 Million Contract to RxMP Therapeutics, Inc.](https://finance.yahoo.com/healthcare/articles/darpa-awards-10-7-million-164300934.html) - Yahoo Finance